文献速递临床试验与 GCP基础与转化研究

联合HIV-1广谱中和抗体在病毒血症个体中的安全性与抗病毒活性

Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals.
PubMed 文献 · Nat Med · 2018-09-26

4名双抗体敏感病毒感染者平均病毒载量下降2.05 log10 copies/ml,且首次输注后三个月内维持显著降低,无人对两种抗体同时产生耐药。

要点

  • 联合两种bNAb在HIV-1病毒血症个体中耐受良好。
  • 双抗体敏感者病毒载量平均降2.05 log10 copies/ml,维持三个月。
  • 未观察到对两种抗体同时耐药,但需更大样本验证。

核心结论

  • 两种强效bNAb联合输注在HIV-1病毒血症个体中安全且可显著降低病毒载量并维持三个月。
  • 双抗体敏感个体未出现对两种抗体同时耐药。

主要发现

  • 输注30 mg/kg的每种抗体耐受良好。
  • 4名双抗体敏感者平均HIV-1病毒载量下降2.05 log10 copies/ml。
  • 首次输注后三个月内病毒载量维持显著降低(最多三次输注)。
  • 上述4名个体均未对两种抗体同时产生耐药。

临床怎么用

  • 联合bNAb策略可能为HIV-1病毒血症个体提供短期病毒控制,但需更大规模研究确认疗效。

局限性

  • 样本量小(7名个体),需更大研究验证疗效及耐药限制。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Monotherapy of HIV-1 infection with single antiretroviral agents is ineffective because error-prone HIV-1 replication leads to the production of drug-resistant viral variants1,2. Combinations of drugs can establish long-term control, however, antiretroviral therapy (ART) requires daily dosing, can cause side effects and does not eradicate the infection3,4. Although anti-HIV-1 antibodies constitute a potential alternative to ART5,6, treatment of viremic individuals with a single antibody also results in emergence of resistant viral variants7-9. Moreover, combinations of first-generation anti-HIV-1 broadly neutralizing antibodies (bNAbs) had little measurable effect on the infection10-12. Here we report on a phase 1b clinical trial ( NCT02825797 ) in which two potent bNAbs, 3BNC11713 and 10-107414, were administered in combination to seven HIV-1 viremic individuals. Infusions of 30 mg kg-1 of each of the antibodies were well-tolerated. In the four individuals with dual antibody-sensitive viruses, immunotherapy resulted in an average reduction in HIV-1 viral load of 2.05 log10 copies per ml that remained significantly reduced for three months following the first of up to three infusions. In addition, none of these individuals developed resistance to both antibodies. Larger studies will be necessary to confirm the efficacy of antibody combinations in reducing HIV-1 viremia and limiting the emergence of resistant viral variants.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Bar-On Y, Gruell H, Schoofs T, et al. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals. Nat Med. 2018. PMID: 30258217. doi:10.1038/s41591-018-0186-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。